Marinomed Marches Towards Approval For Hay Fever Drug

 
• By Kevin Grogan

With Budesolv hitting key endpoints in a Phase III allergy trial, the Austrian biotech is stepping up its partnership discussions for the allergic rhinitis drug.

Sneezing
Marinomed looks for a slice of lucrative hay fever market • Source: Shutterstock

More from Sensory

More from Therapy Areas